366 related articles for article (PubMed ID: 21469140)
1. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.
Andreopoulou E; Yang LY; Rangel KM; Reuben JM; Hsu L; Krishnamurthy S; Valero V; Fritsche HA; Cristofanilli M
Int J Cancer; 2012 Apr; 130(7):1590-7. PubMed ID: 21469140
[TBL] [Abstract][Full Text] [Related]
2. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K
Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T;
Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854
[TBL] [Abstract][Full Text] [Related]
4. Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
Danila DC; Samoila A; Patel C; Schreiber N; Herkal A; Anand A; Bastos D; Heller G; Fleisher M; Scher HI
Cancer J; 2016; 22(5):315-320. PubMed ID: 27749322
[TBL] [Abstract][Full Text] [Related]
5. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer.
Van der Auwera I; Peeters D; Benoy IH; Elst HJ; Van Laere SJ; Prové A; Maes H; Huget P; van Dam P; Vermeulen PB; Dirix LY
Br J Cancer; 2010 Jan; 102(2):276-84. PubMed ID: 19953098
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.
Strati A; Kasimir-Bauer S; Markou A; Parisi C; Lianidou ES
Breast Cancer Res; 2013 Mar; 15(2):R20. PubMed ID: 23497487
[TBL] [Abstract][Full Text] [Related]
9. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
[TBL] [Abstract][Full Text] [Related]
10. CTCs in metastatic breast cancer.
Giordano A; Cristofanilli M
Recent Results Cancer Res; 2012; 195():193-201. PubMed ID: 22527507
[TBL] [Abstract][Full Text] [Related]
11. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch
Neumann MH; Schneck H; Decker Y; Schömer S; Franken A; Endris V; Pfarr N; Weichert W; Niederacher D; Fehm T; Neubauer H
Biotechnol Prog; 2017 Jan; 33(1):125-132. PubMed ID: 27126369
[TBL] [Abstract][Full Text] [Related]
13. Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®.
Gorges TM; Stein A; Quidde J; Hauch S; Röck K; Riethdorf S; Joosse SA; Pantel K
PLoS One; 2016; 11(5):e0155126. PubMed ID: 27182774
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
[TBL] [Abstract][Full Text] [Related]
15. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
16. A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients.
Kim SJ; Masago A; Tamaki Y; Akazawa K; Tsukamoto F; Sato J; Ozawa T; Tsujino Y; Noguchi S
Breast Cancer Res Treat; 2011 Aug; 128(3):765-73. PubMed ID: 21630023
[TBL] [Abstract][Full Text] [Related]
17. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
18. Comparison of analytic performances of Cellsearch and iFISH approach in detecting circulating tumor cells.
Sheng Y; Wang T; Li H; Zhang Z; Chen J; He C; Li Y; Lv Y; Zhang J; Xu C; Wang Z; Huang C; Wang L
Oncotarget; 2017 Jan; 8(5):8801-8806. PubMed ID: 28187533
[TBL] [Abstract][Full Text] [Related]
19. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
20. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
